Literature DB >> 7930911

Clinical features of malignant transformation in benign laryngeal papillomata.

B Singh1, R Ramsaroop.   

Abstract

Laryngeal papillomata can undergo spontaneous malignant transformation without being detected histologically and, in some instances, the disease may become so advanced, before the diagnosis is confirmed, that it is beyond any form of curative treatment. Because of this limitation imposed by histopathological investigation, a study was undertaken in 17 adults with benign laryngeal papillomata, (three of whom underwent malignant transformation) to determine whether malignant transformation can be predicted from the clinical behaviour of the tumour. The following features were analysed: age, sex, patient's symptoms, frequency of excision of the papillomata, site of lesion, presence or absence of laryngeal oedema, the need for tracheostomy, vocal fold mobility and presence or absence of cervical lymph nodes. It was found that decreased vocal fold mobility, the presence of cervical lymph nodes, exuberant and rapid growth requiring very frequent excisions, oedema of the larynx with airway obstruction requiring a tracheostomy are clinical features suggestive of malignant transformation.

Entities:  

Mesh:

Year:  1994        PMID: 7930911     DOI: 10.1017/s0022215100127720

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  MALIGNANT TRANSFORMATION IN A YOUNG ADULT WITH RECURRENT LARYNGEAL PAPILLOMATOSIS.

Authors:  A Behl; E James; P Kelkar; N Chawla
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Prognostic value of clinical findings in histologically verified adult-onset laryngeal papillomas.

Authors:  L M Aaltonen; J Peltomaa; H Rihkanen
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 3.  A possible role for human papillomaviruses in head and neck cancer.

Authors:  B M Steinberg; T P DiLorenzo
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.